Skip to main content
. 2017 Oct 3;8(54):93179–93185. doi: 10.18632/oncotarget.21452

Figure 2. Fixed-effects model of hazard ratio (95% CI) of PFS associated with therapy with or without anti-VEGF agents.

Figure 2